VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

AACR 2021 | TG6002, an oncolytic virus induces expression of a pro-drug activating enzyme in advanced GI cancers

Kaidre Bendjama, Transgene, Strasborg, France, presents the findings of an ongoing Phase I study evaluating oral flucytosine (5-FC) in combination with TG6002, an oncolytic virus encoding FCU1, an enzyme that converts 5-FC to 5-FU, in patients with gastrointestinal carcinomas. TG6002 is found to locate to tumors following intravenous administration, remains active, and effectively expresses FCU1 in tumor tissue, and the study evaluating TG6002 is continuing with escalating doses of virus. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.

Disclosures

Kaidre Bendjama is a full-time employee of Transgene SA.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter